Case Report
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2014; 2(6): 228-231
Published online Jun 16, 2014. doi: 10.12998/wjcc.v2.i6.228
Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports
Sabino De Placido, Pasquale Rescigno, Piera Federico, Carlo Buonerba, Davide Bosso, Livio Puglia, Michela Izzo, Tania Policastro, Giuseppe Di Lorenzo
Pasquale Rescigno, Piera Federico, Carlo Buonerba, Davide Bosso, Livio Puglia, Michela Izzo, Tania Policastro, Sabino De Placido, Giuseppe Di Lorenzo, Genitourinary Cancer Section, Medical Oncology, Department of Clinical Medicine, Federico II University, Napoli 80140, Italy
Author contributions: De Placido S and Rescigno P contributed to the drafting of the manuscript; Federico P, Buonerba C, Bosso D, Puglia L, Izzo M and Policastro T contributed to the acquisition of the data; De Placido S and Di Lorenzo G contributed to the critical revision of the manuscript.
Correspondence to: Giuseppe Di Lorenzo, MD, PhD, Genitourinary Cancer Section, Medical Oncology, Department of Clinical Medicine, Federico II University, Corso Umberto I, Napoli 80140, Italy. giuseppedilorenzoncol@hotmail.com
Telephone: +39-081-7463660 Fax: +39-081-2203147
Received: January 5, 2014
Revised: March 31, 2014
Accepted: May 8, 2014
Published online: June 16, 2014
Processing time: 166 Days and 2.8 Hours
Abstract

Prostate cancer is the most common non-cutaneous malignancy for men. The skeleton is the most common metastatic site but, following an improvement in survival, metastases in uncommon sites are being found more frequently in clinical practice, especially brain metastases. Despite the new drugs now available for metastatic castration resistant prostate cancer, no clinical evidence exists about their effectiveness on brain metastases. We describe the clinical history of 3 patients treated with cabazitaxel plus whole brain radiotherapy. These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.

Keywords: Cabazitaxel; Brain metastases; Prostate cancer

Core tip: Due to the improvement in terms of survival, the incidence of brain metastases (BMs) has increased in patients with metastatic castration resistant prostatic cancer (mCRPC). Despite the large number of treatments now available, the prognosis of patients with BMs is still poor. First, we demonstrate the efficacy of cabazitaxel on brain mestastases in three CRPC patients and then show its profile of tolerability in combination with whole brain radiotherapy.